文献速递前列腺癌

高强度聚焦超声局灶治疗后前列腺特异性抗原下降百分比的作用:大型多中心系列结果

The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.
PubMed 文献 · Eur Urol · 2020-05-19

本研究回顾性分析703例接受高强度聚焦超声局灶治疗的低至中危前列腺癌患者,评估PSA下降百分比对后续追加治疗或根治性治疗的预测价值。中位随访41个月,PSA下降百分比中位值为73%,为独立预测因子;下降>90%者5年内追加治疗概率20%,<10%者约70%。

要点

  • 局灶治疗后PSA下降百分比是追加治疗或根治性治疗的独立预测因子
  • PSA下降>90%者5年内追加治疗概率为20%
  • PSA下降<10%者5年内追加治疗概率约70%

核心结论

  • PSA下降百分比可用于预测局灶治疗后追加治疗或根治性治疗的可能性,应纳入随访策略。

研究设计与样本

  • 回顾性多中心队列研究,纳入703例接受局灶治疗的低至中危前列腺癌患者,中位随访41个月。

主要发现

  • 总体追加治疗率为30%,根治性治疗率为13%。
  • PSA下降百分比中位值为73%。
  • Cox多变量分析显示PSA下降百分比是追加治疗的独立预测因子(HR 0.96;p < 0.001)。
  • Cox多变量分析显示PSA下降百分比是根治性治疗的独立预测因子(HR 0.97;p < 0.001)。
  • PSA下降>90%者5年内追加治疗概率为20%;下降<10%者5年内追加治疗概率约70%。

关键数值与推荐

  • PSA下降>90%:5年内追加治疗概率20%。
  • PSA下降<10%:5年内追加治疗概率约70%。
  • PSA下降百分比每增加1%,追加治疗风险HR 0.96(p < 0.001),根治性治疗风险HR 0.97(p < 0.001)。

临床怎么用

  • 利用PSA下降百分比辅助制定局灶治疗后随访计划。
  • 在局灶治疗后患者咨询中参考PSA下降百分比评估追加治疗风险。

局限性

  • 回顾性研究设计。
  • 局灶治疗领域缺乏标准化随访策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Focal therapy (FT) for prostate cancer (PCa) is emerging as a novel therapeutic approach for patients with low- to intermediate-risk disease, in order to provide acceptable oncological control, whilst avoiding the side effects of radical treatment. Evidence regarding the ideal follow-up strategy and the significance of prostate-specific antigen (PSA) kinetics after treatment is needed. In this study, we aimed to assess the value of the percentage of PSA reduction (%PSA reduction) after FT in predicting the likelihood of any additional treatment or any radical treatment. We retrospectively analysed a multicentre cohort of 703 men receiving FT for low- and intermediate-risk PCa. Overall, the rates of any additional treatment and any radical treatment were 30% and 13%, respectively. The median follow-up period was 41 mo. The median %PSA reduction after FT was 73%. At Cox multivariable analysis, %PSA reduction was an independent predictor of any additional treatment (hazard ratio [HR]: 0.96; p < 0.001) and radical treatment (HR: 0.97; p < 0.001) after FT. For %PSA reduction of>90%, the probability of any additional treatment within 5 yr was 20%. Conversely, for %PSA reduction of <10%, the probability of receiving any additional treatment within 5 yr was roughly 70%. This study is the first to assess the role of %PSA reduction in the largest multicentre cohort of men receiving FT for PCa. Given the lack of standardised follow-up strategies in the FT field, the use of the %PSA reduction should be considered. PATIENT SUMMARY: The percentage of prostate-specific antigen reduction is a useful tool to assess men following focal therapy (FT). It can assist the urologist in setting up an appropriate follow-up and during post-FT patient counselling.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Stabile A, Orczyk C, Giganti F, et al. The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. Eur Urol. 2020. PMID: 32444261. doi:10.1016/j.eururo.2020.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。